药明巨诺
JW Therapeutics

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026; (2) RETIREMENT OF DIRECTORS, CHANGE OF CHAIRMAN; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEE

Reference is made to the circular of JW (Cayman) Therapeutics Co. Ltd (the "**Company**") dated May 26, 2026 (the "**Circular**") incorporating, amongst others, the notice (the "**Notice**") of annual general meeting of the Company (the "**AGM**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the AGM held on June 26, 2026, all the proposed ordinary resolutions as set out in the Notice were taken by poll.

As at the date of the AGM, the total number of issued shares of the Company was 416,729,433 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There were (i) no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System) and as such no voting rights of treasury shares have been exercised at the AGM; and (ii) no repurchased Shares which are pending cancellation and should therefore be excluded from the total number of Shares in issue for the purposes of the AGM. There was no restriction on any Shareholder casting votes on any of the proposed resolutions at the AGM. There was no Share entitling the Shareholders to attend and vote only against the proposed resolutions at the AGM. No party has stated its intention in the Circular that it would vote against any proposed resolution or that it would abstain from voting at the AGM.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS			**Number of votes cast and approximate percentage of total number of votes cast**	
			For	**Against**
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2025 and the reports of the directors and auditor thereon.		43,551,514 99.995408%	2,000 0.004592%
2(a).	(i)	To re-elect Mr. Feng Tian as an executive director of the Company.	43,551,514 99.995408%	2,000 0.004592%
	(ii)	To re-elect Dr. Cheng Liu as a non-executive director of the Company.	19,691,938 45.213201%	23,861,576 54.786799%
	(iii)	To re-elect Dr. Sungwon Song as a non-executive director of the Company.	19,691,938 45.213201%	23,861,576 54.786799%
	(iv)	To re-elect Dr. Debra Yu as an independent non-executive director of the Company.	43,551,514 99.995408%	2,000 0.004592%
2(b).	To authorise the board of directors of the Company (the "**Board**") to fix the remuneration of the directors of the Company (the "**Directors**").		43,551,514 99.995408%	2,000 0.004592%
3.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending December 31, 2026.		41,984,229 96.396881%	1,569,285 3.603119%
4(A).	To give a general mandate to the Directors to offer, allot, issue and deal with additional shares in the Company (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares).		41,984,229 96.396881%	1,569,285 3.603119%
4(B).	To give a general mandate to the Directors to repurchase shares in the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares).		43,551,514 99.995408%	2,000 0.004592%

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
4(C).	To extend the general mandate granted to the Directors to allot, issue and deal with shares by the number of shares repurchased by the Company.	41,984,229 96.396881%	1,569,285 3.603119%

The Board consists of eight Directors, three of whom presented at the AGM. Dr. Cheng Liu, Dr. Yiping James Li, Ms. Xing Gao, Dr. Sungwon Song and Dr. Debra Yu did not attend the AGM due to other work arrangements.

Please refer to the Notice for the full text of the resolutions.

As more than 50% of the votes were cast in favour of the above-mentioned ordinary resolutions No. 1, No. 2(a) (i), No. 2(a) (iv) to No. 4(C), the said proposed ordinary resolutions were duly passed by way of poll at the AGM.

As less than 50% of the votes were cast in favour of the above-mentioned ordinary resolution 2(a) (ii), 2(a) (iii), the said proposed ordinary resolution was duly not passed by way of poll at the AGM.

RETIREMENT OF DIRECTORS, CHANGE OF CHAIRMAN AND CHANGE IN COMPOSITION OF BOARD COMMITTEE

As indicated above, the ordinary resolutions no. 2(a)(ii) and no. 2(a)(iii) regarding the re-election of Dr. Cheng Liu ("**Dr. Liu**") as non-executive Director and Dr. Sungwon Song ("**Dr. Song**") as non-executive Director were not passed at the AGM. Each of Dr. Liu and Dr. Song has therefore retired as non-executive Director with effect from the conclusion of the AGM (the "**Retirement**").

The Board is not aware of any disagreement with Dr. Liu and Dr. Song or any matters in relation to the Retirement that needs to be brought to the attention of the Shareholders and the Stock Exchange.

Immediately following the Retirement, Dr. Liu ceased to be the Chairman of the Board (the "**Chairman**") and Dr. Song ceased to be a member of remuneration committee of the Company (the "**Remuneration Committee**"). Mr. Feng Tian ("**Mr. Tian**") has been appointed as the Chairman with effect from June 26, 2026. Upon the appointment, Mr. Tian will assume the dual roles of the Chairman and the chief executive officer of the Company (the "**Chief Executive Officer**"). Accordingly, notwithstanding that the code provision C.2.1

in Part 2 of the Corporate Governance Code in Appendix C1 to the Listing Rules (the "**CG Code**") provides that the roles of Chairman and chief executive officer should be separate and should not be performed by the same individual, the Board has confidence in vesting the roles of both the Chairman and the Chief Executive Officer in Mr. Tian and believes that this will ensure the Group has consistent leadership and could make and implement the business strategies of the Group more effectively. Therefore, the Board considers that the deviation from the code provision C.2.1 in Part 2 of the CG Code is appropriate in such circumstance. In addition, under the supervision of the Board which currently comprised of an executive Director, two non-executive Directors and three independent non-executive Directors, the Board is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and its shareholders. The Board will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code. Ms. Xing Gao ("**Ms. Gao**"), a non-executive Director, has been appointed as a member of the Remuneration Committee, with effect from June 26, 2026.

Each of Mr. Tian and Ms. Gao's existing roles on the Board remain unchanged. The Board would like to extend a warm welcome to Mr. Tian and Ms. Gao on their new appointments, and would like to express its sincere gratitude to Dr. Liu and Dr. Song for their valuable contributions to the Company during their tenure of office.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Feng Tian
Chairman and Chief Executive Officer

Shanghai, PRC, June 26, 2026

As at the date of this announcement, the Board comprises Mr. Feng Tian as executive Director and Chairman, Dr. Yiping James Li and Ms. Xing Gao as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.

* *For identification purpose only*